logo
Share SHARE
FONT-SIZE Plus   Neg

Cytokinetics Reports Results From Phase II Clinical Trials Evaluating CK-2017357

Cytokinetics, Inc. (CYTK) announced encouraging results from two Phase II clinical trials evaluating CK-2017357 in patients with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's Disease.

Jeremy Shefner, Professor and Chair of the Department of Neurology at the Upstate Medical University at the State University of New York, concluded that CK-2017357 appeared to be safe and well-tolerated dosed daily at 125 mg, 250 mg, and 375 for two weeks, and that encouraging trends were observed in the ALSFRS-R and MVV. As expected, plasma concentrations of CK-2017357 were unaffected by co-administration with riluzole, while riluzole levels increased during co-administration with CK-2017357.

Adverse events and clinical assessments during treatment with CK-2017357 appeared similar, with or without co-administration of riluzole at the reduced dose of 50 mg daily. Dizziness, the most commonly reported adverse event, was mostly mild and generally began and resolved early after initiating treatment.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Packaged food producer ConAgra Brands Inc. reported Thursday higher net profit in its fourth quarter with margin strength. Net sales, meanwhile, declined from last year on weak volume. Looking ahead, for fiscal 2018, the company projects higher adjusted earnings and lower to flat sales. The company also reiterated its three-year fiscal 2020 financial algorithm. Best Buy announced Wednesday its plans to introduce Amazon Alexa and Google Home experiences to its 700 locations across the U.S. starting next month as part of its strategy of pushing smart home technology. A nationwide rollout will be complete by the end of the year. The electronics retailer will expand space at selected stores to better showcase how Amazon's Echo and Google Home interact.. So far this year, 23 novel drugs have already received FDA approval. Now let's take a look at the biotech stocks waiting to hear from the FDA in July.
comments powered by Disqus
Follow RTT